Results 51 to 60 of about 6,174,751 (218)

Subclinical myocardial changes after hematopoietic stem cell transplantation: limited predictive value of early biomarkers and strain imaging

Cardio-Oncology
Background Cardiotoxicity is a relevant late complication after hematopoietic stem cell transplantation. Early identification of subclinical myocardial injury could allow preventive interventions, yet the optimal diagnostic approach in this setting ...
Ana Carolina Oliver, Federico Superchi, Roberto Superchi, Matilde Canabal, Carolina Errecarte, Ricardo Mosquera, Ada Caneiro, Silvia Pierri, Sebastian Galeano, Eloisa Riva, Laura Bello, Regis Gai, Silvana Jubin, Pablo Muxi   +13 more
doaj   +1 more source

Peripheral blood CD34+ peak during mobilisation as an additional parameter to assess PBSC inoculum adequacy autologous HSCT

Frontiers in Immunology
BackgroundAfter autologous haematopoietic stem cell transplantation (HSCT), the infused CD34+ cell dose is usually considered essential for assessing the adequacy of the peripheral blood progenitor cells (PBSC) inoculum.MethodsIn a cohort of 302 patients
Giuseppe Milone, Giuseppe Milone, Emanuele Martorana, Maria Grazia Camuglia, Salvatore Leotta, Andrea Spadaro, Giulia Giuffrida, Gaetano Moschetti, Federica Galbo, Paola Scirè, Giulio Antonio Milone, Giordana Brunetti, Paolo Castorina, Paolo Castorina, Paolo Castorina   +14 more
doaj   +1 more source

EDTA‐induced pseudothrombocytopenia in hematopoietic stem cell donor

Clinical Case Reports, 2023
We herein report a case of peripheral blood stem cell transplantation (PBSCT) involving a donor with EDTA‐induced pseudothrombocytopenia (PTCP). The apheresis product was inspected for 24 h and there was no platelet clumping or thrombocytopenia.
Misato Tsubokura, Minoru Kojima, Saori Nakabayashi, Noriko Takahashi, Sayaka Takeuchi, Yu Aruga, Chiaki Ikeda, Naoki Maezawa, Koji Okazaki, Sanshiro Uchida, Mizuki Watanabe, Jun Aoki, Ayumu Ito, Takashi Tanaka, Yoshihiro Inamoto, Sung‐Won Kim, Hiromichi Matsushita, Takahiro Fukuda   +17 more
doaj   +1 more source

Busulfan in Hematopoietic Stem Cell Transplantation

Biology of Blood and Marrow Transplantation, 2009
The development of intravenous busulfan (Bu) and its incorporation in the preparative regimens for allogeneic stem cell transplantation has changed transplantation for myelogenous malignancies. Bypassing the oral route to achieve 100% bioavailability translated into improved control over drug administration, with increased safety and reliability of ...
Ciurea, Stefan O., Andersson, Borje S.
openaire   +2 more sources

Post-stem cell transplant maintenance for pediatric acute leukemias: insights from a Brazilian institution with a Latin American perspective

Frontiers in Oncology
IntroductionIn resource-limited countries, access to advanced therapies like CAR T-cell therapy is often unattainable. Clinical trials face challenges, with pediatric populations frequently excluded or experiencing significant delays. This highlights the
Carla Nolasco Monteiro Breviglieri, Roseane Vasconcelos Gouveia, Roseane Vasconcelos Gouveia, Valéria Cortez Ginani, Valéria Cortez Ginani, Camila Noronha Santos, Milena Reis Santos de Oliveira, Anna Beatriz Willemes Batalha, Gabriella Sayuri de Alencar, Edna Harumi Goto, Juliana Francielle Marques, Marcia Puato Vieira Pupim, Adriana Seber, Adriana Seber   +13 more
doaj   +1 more source

Blinatumomab-induced remission followed by haploidentical transplantation in pediatric relapsed/refractory pre-B ALL: a multicenter study in Mexico

Frontiers in Oncology
BackgroundPrecursor B-cell acute lymphoblastic leukemia (pre-B ALL) is the most common pediatric cancer worldwide, with cure rates exceeding 85% in high-income countries.
Alberto Olaya-Vargas, Alberto Olaya-Vargas, Haydee Salazar-Rosales, Yadira Melchor-Vidal, Martín Pérez-García, Annecy Herver-Olivares, Gerardo López-Hernández, Nideshda Ramírez-Uribe, Nideshda Ramírez-Uribe, Cesar Galván-Díaz, Irlanda Campos-Pérez, Pilar Cubria-Juárez, Angeles Del Campo-Martínez, Norma López-Santiago, Rocio Cárdenas-Cardos, Rocio Cárdenas-Cardos, Cesar Cárdenas-Pérez Gallardo, Ignacio Mora-Magaña, Jaime Shalkow-Klincovstein   +18 more
doaj   +1 more source

Low-dose post-transplant cyclophosphamide can mitigate GVHD and enhance the G-CSF/ATG induced GVHD protective activity and improve haploidentical transplant outcomes

OncoImmunology, 2017
Use of high-dose, post-transplant cyclophosphamide (PTCy) results in low rates of graft-versus-host-disease (GVHD) and favorable immune reconstitution, although with higher rates of relapse and somewhat high rates of graft failure.
Yu Wang, Ying-Jun Chang, Lu Chen, Lan-Ping Xu, Zhi-Lei Bian, Xiao-Hui Zhang, Chen-Hua Yan, Kai-Yan Liu, Xiao-Jun Huang   +8 more
doaj   +1 more source

Impact of Early Intrapatient Variability of Tacrolimus Concentrations on the Risk of Graft-Versus-Host Disease after Allogeneic Stem Cell Transplantation Using High-Dose Post-Transplant Cyclophosphamide

Pharmaceuticals, 2022
Tacrolimus (Tac) is a pivotal immunosuppressant agent used to prevent graft-versus-host disease (GVHD) after allogeneic stem cell transplantation (alloHSCT).
Daniel N. Marco, María Queralt Salas, Gonzalo Gutiérrez-García, Inés Monge, Gisela Riu, Esther Carcelero, Joan Ramón Roma, Noemí Llobet, Jordi Arcarons, María Suárez-Lledó, Nuria Martínez, Alexandra Pedraza, Ariadna Domenech, Laura Rosiñol, Francesc Fernández-Avilés, Álvaro Urbano-Ispízua, Montserrat Rovira, Mercè Brunet, Carmen Martínez   +18 more
doaj   +1 more source

Perforin gene transfer into hematopoietic stem cells improves immune dysregulation in murine models of perforin deficiency [PDF]

, 2015
Defects in perforin lead to the failure of T and NK cell cytotoxicity, hypercytokinemia, and the immune dysregulatory condition known as familial hemophagocytic lymphohistiocytosis (FHL).
Montiel-Equihua, CA, Arumugam, P, Carmo, M, Risma, KA, Blundell, MP, Hontz, AE, Jordan, MB, Gaspar, HB, Malik, P, Thrasher, AJ, Tiwari, S, Schambach, A, Baum, C, Alonso-Ferrero, ME   +13 more
core  

The novel ETV6::RARA fusion gene, identified in acute promyelocytic leukemia, is sensitive to invitro all-tans retinoic acid and arsenic trioxide administrations

Annals of Hematology
Acute promyelocytic leukemia (APL) is characterized by the presence of PML::RARA fusion gene, and a favorable response to all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) administration.
Mohammad Arian Hassani, Dan Huang, Yuan Gao, Xuehong Zhang, Ziheng Tang, Yanan Huang, Yingxin Wang, Xijia Wang, Jinsong Yan   +8 more
doaj   +1 more source